We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Transgenic Plants Produce Cervical Cancer Vaccine

By Biotechdaily staff writers
Posted on 29 Aug 2003
German researchers have genetically engineered plants to produce 15 virus-like particles of the human papillomavirus (HPV) that could be used in the creation of vaccines or as edible vaccines themselves for cervical cancer. Their work was reported in the September 2003 issue of the Journal of Virology.

Cervical cancer is linked to infection with HPV. Because it is the third most common cancer among women, there is a strong need for the development of an HPV preventive vaccine. In the study, tobacco and potato plants were genetically engineered to produce a major structural protein of HPV. When the protein was purified and administered to mice, it induced an immune response. When the potatoes were fed to mice, they also induced an immune response, although not as significant.

"Here, we demonstrated as a first step that it is possible to produce transgenic plants expressing the HPV 16 L1 protein in a form appropriate for immunization purposes,” said the researchers, from the Max Planck Institute in Golm (Germany).




Related Links:
Max Planck

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Automatic CLIA Analyzer
Shine i6000
New
Silver Member
Connectivity Solution
EKF Link

Latest BioResearch News

Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
29 Aug 2003  |   BioResearch

Population-Scale Proteomics Study Identifies New Genetic-Protein Links
29 Aug 2003  |   BioResearch

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
29 Aug 2003  |   BioResearch